Management of acne vulgaris: summary of NICE guidance

Jingyuan Xu,1,2 clinical fellow and dermatology registrar, Ifigeneia Mavranezouli,1,3 senior health economist, Laura Kuznetsov,1 systematic reviewer, M. Stephen Murphy,1 clinical advisor, Eugene Healy,4,5 topic advisor and professor and honorary consultant dermatologist, on behalf of the Guideline Committee

1 National Guideline Alliance, Royal College of Obstetricians and Gynaecologists, London, UK
2 University of Manchester, Manchester, UK
3 Research Department of Clinical, Educational & Health Psychology, University College London, London, UK
4 University of Southampton, Southampton, UK
5 University Hospital Southampton NHS Foundation Trust, Southampton, UK

Correspondence to: J Xu j.xu@nhs.net

Box Start

What you need to know

• For mild to moderate acne, first-line treatment options include a fixed combination of (a) topical adapalene with topical benzoyl peroxide, (b) topical tretinoin with topical clindamycin, or (c) topical benzoyl peroxide with topical clindamycin

• For moderate to severe acne, first-line treatment options include (a) and (b) of those above, and:

  (d) a fixed combination of topical adapalene with topical benzoyl peroxide, plus either oral lymecycline or oral doxycycline

  (e) topical azelaic acid plus either oral lymecycline or oral doxycycline

• Topical or oral antibiotics should not be used as monotherapy or in combination with each other

• Review treatment response at 12 weeks; options that include an antibiotic (topical or oral) should be continued for more than 6 months only in exceptional circumstances

• Consider referral to a consultant dermatologist-led team if moderate to severe acne has failed to respond to a 12-week course of treatment that includes an oral antibiotic or if mild to moderate acne has failed to respond adequately to two different 12-week courses of treatment

Box End

Acne vulgaris is the eighth most common disease globally, resulting in >70 000 patients being referred for specialist care in the UK each year.1,2 While acne vulgaris most often affects adolescents, it is not uncommon in adults and can occur in children. The clinical features vary depending on its severity and its associated psychological impact. Acne vulgaris may persist and lead to pigmentary changes and permanent scarring. This article summarises the guideline from the National Institute for Health and Care Excellence (NICE) on the management of acne vulgaris.3 This guidance was developed with the aim to improve the
management of acne vulgaris and reduce sequelae, with a clear framework of referral to more specialised services as appropriate. Throughout the summary and guideline, “acne” refers to acne vulgaris unless otherwise stated.

<table>
<thead>
<tr>
<th>Box Start</th>
<th>What the guideline covers</th>
</tr>
</thead>
<tbody>
<tr>
<td>▪ First-line treatment options stratified by acne severity including advantages and disadvantages with clear stepwise algorithm according to treatment response</td>
<td></td>
</tr>
<tr>
<td>▪ 12-week treatment course with timely review and assessment of response, including guidance on duration of antibiotic use</td>
<td></td>
</tr>
<tr>
<td>▪ Treatment options for maintenance and acne relapse, and recommendations on skin care</td>
<td></td>
</tr>
<tr>
<td>▪ Clear referral criteria including mental health services if a person with acne experiences significant psychological distress or a mental health disorder</td>
<td></td>
</tr>
<tr>
<td>▪ Specialist care options in a consultant dermatologist-led team setting, including physical treatments and treatment for acne-related scarring</td>
<td></td>
</tr>
</tbody>
</table>

| Box End |

**Recommendations**

NICE recommendations are based on systematic reviews of best available evidence and explicit consideration of cost effectiveness. Network meta-analysis (NMA) of randomised controlled trials (RCTs) was used to synthesise evidence on treatment efficacy (change in total lesion count from baseline), acceptability (discontinuation for any reason), and tolerability (discontinuation due to side effects). NMA was conducted separately for people with mild to moderate acne vulgaris and people with moderate to severe acne vulgaris. Pairwise meta-analysis was used to compare outcomes where evidence was more limited across treatments or was treatment-specific (e.g. adverse events). When minimal evidence was available, recommendations were based on the Guideline Committee’s experience and opinion of what constitutes good practice. Evidence levels for the recommendations are given in italic in square brackets.

**Skin care advice**

Clinicians are often asked for skin care advice, and this is an important topic for people with acne. The advice given to people with acne varies, and so the guideline provides recommendations aimed at standardising practice.

- Advise people with acne to use a non-alkaline (skin pH neutral or slightly acidic) synthetic detergent (syndet) cleansing product twice daily on acne-prone skin. *Based on moderate to very low quality evidence*
- Advise people with acne who use skincare products (for example, moisturisers) and sunscreens to avoid oil based and comedogenic preparations. *Based on the experience and opinion of the Guideline Committee (GC)*
• Advise people with acne who use make-up to avoid oil based and comedogenic products, and to remove make-up at the end of the day. [Based on the experience and opinion of the GC]

• Advise people that persistent picking or scratching of acne lesions can increase the risk of scarring. [Based on the experience and opinion of the GC]

Managing acne vulgaris

The infographic summarises the recommendations for first-line treatment options, taking account of the severity of acne and the person’s preferences, and after a discussion of the advantages and disadvantages of each option.

A course of treatment is 12 weeks, and the importance of completing the course should be explained to the person as positive effects can take six to eight weeks to become noticeable.

• A fixed combination of topical adapalene with topical benzoyl peroxide for any acne severity.

• A fixed combination of topical tretinoin with topical clindamycin for any acne severity

• A fixed combination of topical benzoyl peroxide with topical clindamycin for mild to moderate acne.

• A fixed combination of topical adapalene with topical benzoyl peroxide, together with either oral lymecycline or oral doxycycline for moderate to severe acne.

• Topical azelaic acid with either oral lymecycline or oral doxycycline for moderate to severe acne.  
  [All the above based on moderate to very low quality of evidence synthesised in NMA of randomised control trials, pairwise meta-analysis, and health economic analysis]

• Consider topical benzoyl peroxide monotherapy as an alternative treatment to the first-line treatment options, if these treatments are contraindicated or the person wishes to avoid using a topical retinoid or an oral antibiotic (topical or oral). [Based on moderate to very low quality of evidence synthesised in NMA of randomised control trials, pairwise meta-analysis, and health economic analysis]

• For people with moderate to severe acne who cannot tolerate or have contraindications to oral lymecycline or oral doxycycline, consider replacing these medicines in the combination treatments with trimethoprim or with an oral macrolide (for example, erythromycin). [Based on the experience and opinion of the GC]

• To reduce the risk of skin irritation associated with topical treatments such as benzoyl peroxide or retinoids, start with alternate-day or short-contact application (for example, washing off after an hour). If tolerated, progress to using a standard application. [Based on the experience and opinion of the GC]

Factors to take into account at review

The Guideline Committee noted the importance of timely review and standardisation of the duration of antibiotic use in line with antimicrobial stewardship. People whose acne vulgaris has cleared are often concerned about future management and relapse. The infographic summarises the recommendations for maintenance options after adequate response to treatment.
• Review first-line treatment at 12 weeks and
  - assess whether the person’s acne has improved and whether they have any side effects
  - in people whose treatment includes an oral antibiotic, if their acne has completely cleared consider stopping the antibiotic but continuing the topical treatment
  - in people whose treatment includes an oral antibiotic, if their acne has improved but not completely cleared consider continuing the oral antibiotic, alongside the topical treatment, for up to 12 more weeks.
• Only continue a treatment option that includes an antibiotic (topical or oral) for more than six months in exceptional circumstances. Review at 3-month intervals and stop the antibiotic as soon as possible.
• Be aware that the use of antibiotic treatments is associated with a risk of antimicrobial resistance.
• If acne has cleared, consider maintenance options.
• If acne fails to respond adequately to a 12-week course of a first-line treatment option and at review the severity is
  - mild to moderate, offer another option from the first-line treatment options
  - moderate to severe and the treatment did not include an oral antibiotic, offer another option which includes an oral antibiotic from first-line treatment options
  - moderate to severe and the treatment included an oral antibiotic, consider referral to a consultant dermatologist-led team.
• If mild to moderate acne fails to respond adequately to two different 12-week courses of treatment options, consider referral to a consultant dermatologist-led team.
  [All the above based on the experience and opinion of the GC]

Relapse
Treatment should be offered in a stepwise approach, taking into account the number of treatment courses and the severity of acne at the time of relapse.
• If acne responds adequately to a course of an appropriate first-line treatment but then relapses, consider either
  - another 12-week course of the same treatment, or
  - an alternative 12-week treatment from first-line treatment options.
• If acne relapses after an adequate response to oral isotretinoin and is currently mild to moderate, offer an appropriate first-line treatment option.
• If acne relapses after an adequate response to oral isotretinoin and is currently moderate to severe, offer either
  - a 12-week course of an appropriate first-line treatment option, or
  - re-referral if the person is no longer under the care of the consultant dermatologist-led team.
  [All the above based on the experience and opinion of the GC]

Referral to specialist care
Healthcare professionals should recognise that (a) acne of any severity can cause psychological distress and mental health disorders and (b) the risk of physical scarring increases with the severity and duration of acne. The following referral criteria will improve
outcomes through appropriate implementation of treatment or management strategies for people with acne.

- Urgently refer people with acne fulminans on the same day to the on-call hospital dermatology team, to be assessed within 24 hours.
- Refer people to a consultant dermatologist-led team if any of the following apply
  - there is diagnostic uncertainty about their acne
  - they have acne conglobata
  - they have nodulocystic acne.
- Consider referring people to a consultant dermatologist-led team if they have
  - mild to moderate acne that has not responded to two completed courses of treatment
  - moderate to severe acne which has not responded to previous treatment which contains an oral antibiotic
  - acne with scarring
  - acne with persistent pigmentary changes.
- Consider referring people to a consultant dermatologist-led team if their acne of any severity, or acne-related scarring, is causing or contributing to persistent psychological distress or a mental health disorder.
- Consider referral to mental health services if a person with acne experiences significant psychological distress or a mental health disorder, including those with a current or past history of
  - suicidal ideation or self harm
  - a severe depressive or anxiety disorder
  - body dysmorphic disorder.
- Consider condition-specific management or referral to a specialist (for example, a reproductive endocrinologist) if a medical disorder or medication (including self administered anabolic steroids) is likely to be contributing to a person’s acne.

[All of the above based on the experience and opinion of the GC]

Additional management options in specialist care

In a consultant dermatologist-led team, management options include oral isotretinoin, physical treatments for acne and treatment for acne-related scarring.

- Consider oral isotretinoin for people older than 12 years who have a severe form of acne that is resistant to adequate courses of standard therapy with systemic antibiotics and topical therapy. For example
  - nodulocystic acne
  - acne conglobata
  - acne fulminans
  - acne at risk of permanent scarring

  [Based on moderate to very low quality of evidence synthesised in NMA of randomised control trials, pairwise meta-analysis, and health economic analysis]

- When considering oral isotretinoin for acne take into account the person's psychological wellbeing, and refer them to mental health services before starting treatment if appropriate. [Based on the experience and opinion of the GC]
• Consider photodynamic therapy for people aged 18 and over with moderate to severe acne if other treatments are ineffective, not tolerated, or contraindicated. [Based on moderate to very low quality of evidence synthesised in NMA of randomised control trials, pairwise meta-analysis, and health economic analysis]

• If a person’s acne-related scarring is severe and persists a year after their acne has cleared
  - refer the person to a consultant dermatologist-led team with expertise in scarring management
  - in a consultant dermatologist-led team setting, consider CO₂ laser treatment (alone or after a session of punch elevation) or glycolic acid peel. [Based on high to very low quality evidence, cost analysis, and the experience and opinion of the GC]

Implementation

The main challenges to the implementation of this guidance are

• Service organisation for networks of care is variable: changes to practice will depend on the availability of services (such as mental health services) within a particular local area.

• Primary care resources may be affected, but implementation is likely to lead to later benefits and reductions in resource use from better understanding of and compliance with medication.

• Physical treatments for the management of acne are not part of current practice in the NHS. Therefore, the recommendation will result in a change in current practice and have potential impact on resources and training.

• The availability of treatments for acne-related scarring in NHS centres varies across the country. Additional resources and training may be required in centres offering these treatment options.

Box Start
How patients were involved in the creation of this article
Committee members involved in this guideline included two lay members who contributed to the formulation of the recommendations summarised here.
Box End

Box Start
What is not included in this summary
Please see full NICE guideline3 for recommendations on diet, treatment options for people with polycystic ovary syndrome, maintenance options, isotretinoin prescribing, use of oral corticosteroids in addition to oral isotretinoin, use of intralesional corticosteroids, and information for people with acne scarring.
Box End

Box Start
Details of topical treatment options
• Fixed combination (two active medications in single pharmaceutical product) of topical adapalene (retinoid) with topical benzoyl peroxide

  Formulation with either of these 2 concentrations:
  - 0.1% adapalene with 2.5% benzoyl peroxide
  - 0.3% adapalene with 2.5% benzoyl peroxide

• Fixed combination of topical benzoyl peroxide with topical clindamycin

  Formulation with either of these 2 concentrations:
- 3% benzoyl peroxide with 1% clindamycin
- 5% benzoyl peroxide with 1% clindamycin

**Fixed combination of topical tretinoin (retinoid) with topical clindamycin**
- 0.025% tretinoin with 1% clindamycin

**Topical adapalene (retinoid)**
- 0.1% adapalene

**Topical azelaic acid**
Formulation with either of these 2 concentrations:
- 15% azelaic acid
- 20% azelaic acid

**Topical benzoyl peroxide**
- 5% benzoyl peroxide

---

**Further information on the guidance**

This guidance was developed by the National Guideline Alliance in accordance with NICE guideline methodology ([https://www.nice.org.uk/process/pmg20/chapter/introduction](https://www.nice.org.uk/process/pmg20/chapter/introduction)). A Guideline Committee (GC) was established by the National Guideline Alliance, which incorporated healthcare and allied healthcare professionals (two dermatologists, one paediatric dermatologist, two general practitioners, one specialist nurse in dermatology, one pharmacist, with co-opted members including one gynaecological endocrinologist, one cosmetic dermatologist, one psychologist, one psychiatrist, one dietitian, and one microbiologist) and two lay members.

The GC identified relevant review questions and appraised the best available evidence and evaluated the cost effectiveness of proposed recommendations where possible. Quality ratings of the evidence were based on GRADE methodology ([www.gradeworkinggroup.org](http://www.gradeworkinggroup.org)). These relate to the quality of the available evidence for assessed outcomes or themes rather than the quality of the study. The GC agreed recommendations for clinical practice based on the available evidence or, when evidence was not found, based on their experience and opinion using informal consensus methods.

The scope and the draft of the guideline went through a rigorous reviewing process, in which stakeholder organisations were invited to comment; the GC took all comments into consideration when producing the final version of the guideline.

NICE will conduct regular reviews after publication of the guidance, to determine whether the evidence base has progressed significantly enough to alter the current guideline recommendations and require an update.

**Future research**
The GC made the following research recommendations:
1. What is the efficacy of reduced dose oral isotretinoin in the management of acne vulgaris?
2. What is the most effective first-line treatment option for any severity of acne vulgaris for people with polycystic ovary syndrome?
3. What is the effect of dietary interventions or dietary changes on acne?
4. What skin care advice is appropriate for people with acne?
5. What is the effectiveness of physical treatments (such as light devices) in the treatment of acne vulgaris or persistent acne vulgaris-related scarring?
6. What are the risk factors for acne vulgaris-related scarring?
7. What is the effectiveness of chemical peels for the treatment of acne vulgaris or persistent acne vulgaris-related scarring?

8. What is the effectiveness of hormone modifying agents in the treatment of acne vulgaris?

9. What information and support are valued by people with acne vulgaris?

Box End


The members of the National Guideline Alliance technical team were (listed alphabetically): Zenette Abrahams, Hadil Al-Etabi, Stephanie Arnold, Melissa Bolessa, Nathan Bromham, Shalmali Deshpande, Katharina Dworzynski, Linyun Fou, Jen Francis, Eva Gonzalez Viana, Laura Kuznetsov, Sonniya Lewis, Rachel Marshall, Ifigeneia Mavranezouli, M. Stephen Murphy, Benjamin Purchase, Jingyuan Xu.

The collaborators from the Technical Support Unit (TSU) were: Caitlin Daly, Nicky Welton.

Contributors: All authors contributed to the initial draft of this article, helped revise the manuscript, and approved the final version for the publication.

Funding: IM, LK, and SM received support from the National Guideline Alliance (NGA) at the Royal College of Obstetricians and Gynaecologists (RCOG), which is commissioned and funded by NICE to develop clinical, public health and social care guidelines and write this BMJ summary. No authors received special funding from any other source to write this summary.

Disclaimer: The views expressed in this publication are those of the authors and not necessarily those of NGA, RCOG, or NICE.

Competing interests: We declared the following interests based on NICE’s policy on conflicts of interests (https://www.nice.org.uk/guidance/ng198/documents/register-of-interests).


Schofield J, Grindlay D, Williams H. Skin conditions in the UK: a health care needs assessment. Centre of Evidence Based Dermatology, University of Nottingham, 2009.